Lovastatin Tablet
Product Images NDC 63629-1178

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 63629-1178). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl636291178

Label for Lovastatin Tablets, USP 10 mg by Bryant Ranch Prepack. The label displays the NDC number 63629-1178-1, dosage strength 10 mg prominently, and indicates the package contains 100 tablets. It includes manufacturer information for Carlsbad Technology, Inc., storage instructions, and a barcode. The label is marked Rx only.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of Lovastatin, illustrating its molecular arrangement as shown in the diagram.*

FDA Label Image

Table I (Lov00 0004 02)

A data table summarizing the effect of various coadministered drugs or grapefruit juice on Lovastatin exposure when taken together. It lists number of subjects, dosing of the coadministered drug or grapefruit juice, dosing of Lovastatin, and compares AUC ratios with and without the coadministered drug, indicating changes in Lovastatin exposure.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph illustrating the proportion of participants without acute major coronary events over approximately six years of follow-up. The graph compares two groups: Lovastatin and Placebo, showing a separation favoring Lovastatin, with a noted 37% risk reduction (p < 0.001). The x-axis represents years of follow-up, and the y-axis shows the proportion of participants without events from 0.90 to 1.0.*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table titled 'Table VII Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis.' It lists interacting agents including strong CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, and others, alongside prescribing recommendations such as contraindications and dosage limits for lovastatin. Recommendations include avoiding certain drugs with lovastatin and specific daily dosage limits.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.